Journal of Neural Transmission
Springer Vienna
image
Selegiline: a molecule with innovative potential
DOI 10.1007/s00702-019-02082-0, Volume: 127, Issue: 5,

Table of Contents

Highlights

Notes

Abstract

Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on–off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson’s disease. However, the serious side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors.

Keywords
Tábi, Vécsei, Youdim, Riederer, and Szökő: Selegiline: a molecule with innovative potential

History

The story of the monoamine oxidase B (MAO-B) inhibitors started with the discovery of selegiline (R-deprenyl). The compound was synthesized by Zoltán Ecseri in Chinoin Pharmaceuticals (Budapest, Hungary) in 1962 along with a series of similar, structurally related drug candidates. Their pharmacology was thoroughly studied in the laboratories of Joseph Knoll at Semmelweis University (Budapest, Hungary) (Knoll and Magyar 1972; Magyar et al. 1979; Knoll 1979). They were looking for psychic energizers based on the known antidepressant effect of MAO inhibitors (Knoll et al. 1965). The first clinical study was performed according to this intended indication (Varga and Tringer 1967). However, Knoll and Magyar observed peculiar features of deprenyl different from those of previously used MAO inhibitors, e.g., it lowers blood pressure and is free from “cheese effect”, the severe drug–food interaction of irreversible MAO inhibitor antidepressants. Namely, severe hypertensive crisis can develop when food rich in tyramine is consumed by patients treated by these drugs [for review see Finberg and Gillman (2011)]. The selective inhibitory effect of selegiline on one of the MAO isoforms was identified by Knoll and Magyar (1972). Parallel to their observation, Johnston published that the MAO enzyme exists in two distinct isoforms based on selective inhibition of one of them by clorgyline, which was named MAO-A (Johnston 1968). Selegiline, however, inhibits irreversibly the other isoform, and this was assigned as MAO-B. The other observation of Magyar was that the levorotatory isomer of the chiral deprenyl, R-deprenyl later called selegiline is a more potent inhibitor of MAO-B and has better pharmacological profile compared to the other deprenyl enantiomer (Magyar et al. 1967; Knoll and Magyar 1972).

The two MAO isoforms can be distinguished not only by their selective inhibitors, but they differ in their substrate specificity, as well. Serotonin and noradrenaline are specific substrates of MAO-A explaining the antidepressant and blood pressure increasing effects of its inhibitors (Finberg and Youdim 1983). β-Phenylethylamine was first identified as MAO-B substrate, since the selective inhibition of MAO-B increased the level of this biogenic amine (Reynolds et al. 1978). Only later on was it revealed that dopamine is also a substrate of MAO-B (Glover et al. 1977). Actually, it was shown to be a substrate of both MAO isoenzymes (O’Carroll et al. 1983).

It was the idea of one of us (P. R.) that an MAO inhibitor with favorable side effect profile was worth trying to treat Parkinson’s disease (PD) patients to prevent the serious on–off phenomenon. This suggestion was based on the clinical observations of Birkmayer and Hornykiewicz in the early 1960s that various MAO inhibitors provided mild clinical benefits in the treatment of PD (Birkmayer and Hornykiewicz 1962). However, the potential hypertensive effect of the non-selective irreversible MAO inhibitors restricted their further use. M. Y. informed P. R. about the new selective MAO-B inhibitor compound, selegiline, free from the “cheese effect” and without liver toxicity, which is another problem with some irreversible MAO inhibitors. Although at that time they were not aware that dopamine was a good substrate of MAO-B, furthermore based on rodent studies it was rather regarded as a MAO-A substrate, after some debate P. R., M. Y. and Birkmayer finally concluded that selegiline was worth trying in PD. M. Y. had got some selegiline from Knoll for experimental works and he provided it for starting to treat parkinsonian patients in 1974. The benefit of the treatment with the combination of levodopa and selegiline was first published in 1975 (Birkmayer et al. 1975) and 2 years later its long-term effectiveness was also reported (Birkmayer et al. 1977).

Later on, human post-mortem brain studies revealed that MAO-B isoform was present in the human brain, predominantly in glia (Konradi et al. 1989; Riederer et al. 1987; Collins et al. 1970). In various regions of post-mortem brain of selegiline-treated patients, elevated β-phenylethylamine and dopamine levels were detected (Riederer et al. 1984; Riederer and Youdim 1986), supporting the dopamine-sparing effect of the MAO-B inhibition, which is in line with the clinical findings. Platelet MAO-B inhibition in selegiline-treated patients was also demonstrated (Riederer et al. 1978).

On the proposal of two of us (P. R. and M. Y.) data from PD patients treated for a long time with selegiline in the Lainz Geriatric Hospital, Vienna, were analyzed. The interesting results demonstrated a prolongation of life expectancy for selegiline-treated PD patients first published in 1983 (Birkmayer 1983). The re-analysis of the data by more sophisticated statistical methods showed the same result (Birkmayer et al. 1985). These publications gave a new impetus on preclinical and clinical studies on selegiline aiming at elucidation of its possible neuroprotective effect.

Experimental data from numerous animal and cell culture studies provided evidence that selegiline protects against various neurotoxins, reduces oxidative stress and possesses neurotrophic and antiapoptotic effects. All these properties may contribute to its neuroprotective activity. These preclinical findings were previously thoroughly reviewed (Gerlach et al. 1996; Magyar et al. 2004, 2006; Naoi and Maruyama 2010; Maruyama and Naoi 2013; Szoko et al. 2018).

Clinical studies on selegiline in PD

The increasing amount of preclinical pharmacological data about the possible neuroprotective effect of selegiline raised the hypothesis that it may slow the progression of PD. To prove this concept, several placebo-controlled randomized clinical trials were initiated from the late 1980s. A smaller study of 54 patients published in 1989 was the first reporting that 10 mg/day selegiline treatment delayed the need for levodopa therapy by about 8 months, which was ascribed to a possible disease progression-slowing effect (Tetrud and Langston 1989). However, it was immediately debated because the bare symptomatic effect of selegiline resulting from its dopamine-sparing effect could not be ruled out (Friedhoff 1990). The first large-scale multicenter controlled clinical trial was initiated in 1987 and it also aimed at determining the disease-modifying effect of selegiline in early PD, which was supposed to be related to the recognized antioxidant property of MAO inhibition. Hydrogen peroxide is one of the products of MAO-catalyzed amine oxidation reaction and it can be converted to further reactive oxygen species resulting in cytotoxicity. The inhibition of MAO activity thus may reduce oxidative stress. As the putative mechanism of neuroprotection was the antioxidant property of selegiline, another antioxidant, tocopherol, was also included in the study in addition to placebo as comparator. Eight hundred untreated PD patients were enrolled into this DATATOP study with primary end point of development of disability, necessitating the introduction of levodopa treatment. In the interim reports evaluating the first 12 months of the trial, a 57% reduction in the number of subjects reaching the primary end point was shown (Parkinson Study Group 1989) and 50% less patients had to give up full-time employment (Shoulson 1992) in the 10 mg/day selegiline-treated group. The final report was based on the results of a mean 14 ± 6 months treatment period. Selegiline therapy delayed the time to end point, the need of levodopa treatment, by about 9 months while tocopherol was ineffective. The mechanism of this beneficial effect was not revealed in the study, but the importance of the antioxidant property was questioned. Regarding symptoms control, assessed by Unified PD Rating Scale (UPDRS) and Activity of Daily Living (ADL) scores, selegiline was most effective in the first 3 months of the therapy. However, 2 months after its withdrawal, the motor performance of patients declined (Parkinson Study Group 1993). These findings clearly indicate the symptomatic benefit of selegiline treatment, but its disease-modifying effect was not unequivocally proven. In a continuation of the study, selegiline was administered to all patients who did not reach the primary end point over 21 ± 4 months of observation. There was no significant difference between the previously selegiline- or placebo-treated groups in the time reaching the end point, the need of starting levodopa. The conclusion of the Parkinson Study Group was that the initial benefit of selegiline treatment was not sustained (Parkinson Study Group 1996). In another continuation, those selegiline-treated patients who required levodopa were re-randomized after 5 years to continue selegiline or change to placebo. During the 2 years follow-up, there was no significant difference in combined end points of development of wearing-off, dyskinesia and on–off fluctuation between the treatment groups. However, assessing the distinct motor disturbances, there were less freezing of gait, wearing-off and on–off fluctuation, but more dyskinesia in the selegiline group, which is consistent with its dopamine-potentiating effect (Shoulson et al. 2002). Further smaller studies were also performed to evaluate the advantage of selegiline monotherapy in early PD. Rapid improvement in several parkinsonian symptoms was demonstrated in several short-term studies (Allain et al. 1993; Mally et al. 1995). Some other trials, similarly to DATATOP study, aimed at evaluation of disease-modifying effect of selegiline. In the Finnish study 54 untreated patients were randomized to 10 mg/day selegiline or placebo. The median time to initiation of levodopa treatment was found about 6 months longer (Myllyla et al. 1991) and the necessary dose of levodopa for the sufficient therapeutic effect was about half in the selegiline group (Myllyla et al. 1993). The levodopa dose-sparing effect was not only maintained, but further increased after the 5-year follow-up period. Selegiline treatment also reduced the need of additional dopaminergic therapy (slow release levodopa or dopamine agonist) (Myllyla et al. 1997). In a Swedish study of 157 early PD patients, selegiline significantly delayed the need to start levodopa therapy by about 4 months compared to placebo. Furthermore, the advantage of selegiline treatment in UPDRS scores was maintained after 2 months washout period before levodopa was started suggesting its neuroprotective effect (Palhagen et al. 1998). In the continuation of this study, the advantage of selegiline was also maintained after levodopa was started. Patients after 5 years on selegiline and levodopa combination had nearly ten points lower UPDRS scores, while 19% lower levodopa dose was used compared to levodopa only group (Palhagen et al. 2006). Recently, the benefit of selegiline monotherapy in early PD was also confirmed in a 12-week controlled trial in Japan, further supporting the use of the drug in early Parkinsonism (Mizuno et al. 2017).

These clinical trials unequivocally proved the efficacy of selegiline monotherapy in early PD (Table 1). In addition to symptoms improvement, it delays the introduction of levodopa by 3–9 months and reduces the necessary levodopa dose. Some of the studies also indicate the long-term maintenance of the initial benefit, suggesting neuroprotective effect of early started selegiline treatment.

Table 1
Clinical trials evaluating the effect of selegiline monotherapy in early PD
Design, number of patients (study name)Studied daily doseKey findingsReferences
Double-blind RCT, 54 patients10 mg selegiline vs. placebo8 months delay in the need of initiation of levodopa therapyTetrud and Langston (1989)
Double-blind RCT, 800 patients (DATATOP—Interim report)10 mg selegiline vs. placebo57% reduction in the number of patients needing levodopa after 12 months treatmentParkinson Study Group (1989), Shoulson (1992)
Double-blind RCT, 54 patients10 mg selegiline vs. placebo

6 months delay in the need of initiation of levodopa therapy.

About half dose levodopa was needed in the selegiline group

Myllyla et al. (1991)

Myllyla et al. (1993)

Double-blind RCT, 93 patients10 mg selegiline vs. placeboImproved motor rating and depressive scores after 3 months in the selegiline groupAllain et al. (1993)
Double-blind RCT, 800 patients (DATATOP—final report)10 mg selegiline vs. placebo9 months delay in the need of initiation of levodopa therapyParkinson Study Group (1993)
Double-blind RCT, 20 patients10 mg selegiline vs. placeboImproved motor scores after 3 weeks in the selegiline groupMally et al. (1995)
Open label continuation of DATATOP, 310 patients10 mg selegilineNo difference in benefit of early and late start of selegilineParkinson Study Group (1996)
Double-blind RCT, 157 patients10 mg selegiline vs. placebo

4 months delay in the need of initiation of levodopa therapy.

Improved motor scores were maintained after 2-month washout

Palhagen et al. (1998)
Double-blind RCT, 292 patients

10 mg selegiline vs. placebo

(dose was escalated over 6 weeks)

Improved motor scores after 12 weeks in the selegiline groupMizuno et al. (2017)

In addition to the continuations of monotherapy trials, combinational therapy studies were performed, as well. In the first double-blind randomized trial, 112 patients poorly responding to levodopa were subjected to 7.5 mg/day selegiline or placebo combination therapy. After 8 weeks, significantly more patients showed moderate or better improvement when selegiline was added to levodopa (Takahashi et al. 1994). Olanow et al. compared the deterioration of early PD patients receiving levodopa/carbidopa with or without selegiline combination for 12 months, followed by 2 months selegiline washout period. The UPDRS score was deteriorated by 5.8 ± 1.4 points in the levodopa/carbidopa group, but remained unaltered (0.4 ± 1.3 point deterioration) in the levodopa/carbidopa + selegiline group. Because of the 2 months selegiline washout before the evaluation, these data suggest its disease-modifying rather than barely symptomatic effect (Olanow et al. 1995). Later on, the study design was criticized because there were no placebo and selegiline only groups. However, according to the authors’ answer, for demonstration of benefit of add-on selegiline treatment, the presented design was appropriate (Schulzer 1997). The long-term benefit of addition of selegiline to levodopa treatment was reported by the Norwegian–Danish study group, as well. In the randomized placebo-controlled double-blind trial, combination treatment was continued for 5 years followed by 1-month selegiline washout. At the end of the study, symptoms were less severe and levodopa dose was lower when selegiline was combined to levodopa/benserazide and no symptom worsening was observed after the washout period (Larsen et al. 1999). SELEDO trial evaluated the long-term outcome of early started combination treatment of levodopa with selegiline or placebo in 160 patients. The primary end point was the need of more than 50% increase in levodopa dose for symptoms control. Almost twice longer time (4.9 vs. 2.6 years) was needed to reach the end point in the selegiline combination group (Przuntek et al. 1999).

In addition to prospective studies, retrospective analysis of patient registers was also performed with contradictory results in terms of effect on disease progression. In one of the early reports, no significant difference between selegiline + levodopa and levodopa alone groups was found regarding Hoehn–Yahr stage and motor symptoms in a period of 5 years. The levodopa dose, however, was lower in case of the combination treatment (Brannan and Yahr 1995). The benefit of long-term and/or early started selegiline treatment is indicated by other retrospective data analyses. Mizuno et al. reported that patients on combination of levodopa and selegiline had lower UPDRS scores compared to levodopa only treated group after about 10 years of disease duration. Adding selegiline to levodopa at this time point, the UPDRS score, although improved after the 4-month combination treatment, did not reach the level seen in patients on early started combination therapy (Mizuno et al. 2010). Another study evaluated the factors affecting disease progression in 687 patients assessing the retardation of Hoehn–Yahr stage transition time. It was found that in early PD, at least 3-year selegiline treatment increased the transition times from stage 2 to 2.5 and 2.5 to 3 (Zhao et al. 2011). Table 2 summarizes the results of studies on combinational therapies.

Table 2
Clinical trials and retrospective studies evaluating the effect of selegiline combinational therapy in PD
Design, number of patients (study name)Studied daily doseKey findingsReferences
Double-blind RCT, 112 patients7.5 mg selegiline vs. placebo in combination with levodopaMore improvement after 8 weeks in the selegiline groupTakahashi et al. (1994)
Retrospective, 82 patients10 mg selegiline in combination with levodopa vs. levodopa alone

No difference in motor scores after 1–5 years

Lower levodopa dose needed after 1–3 years in the selegiline group, no difference after 4–5 years

Brannan and Yahr (1995)
Double-blind RCT, 101 patients10 mg selegiline vs. placebo in combination with levodopa and/or bromocriptine

Less disease deterioration after 1 year in the selegiline group.

Benefit was maintained after 2-month washout

Olanow et al. (1995)
Double-blind continuation of Myllyla’s study, 44 patients10 mg selegiline vs. placebo in combination to levodopaLower levodopa dose needed even after 5 years in the selegiline groupMyllyla et al. (1997)
Double-blind RCT, 163 patients10 mg selegiline vs. placebo in combination with levodopa

Less disease deterioration after 5 years in the selegiline group.

Benefit was maintained after 1-month washout

Larsen et al. (1999)
Double-blind RCT, 160 patients10 mg selegiline vs. placebo in combination with levodopaAbout twice longer time to need for 50% increase in levodopa dose in the selegiline groupPrzuntek et al. (1999)
Double-blind continuation of DATATOP, 368 patients10 mg selegiline vs. placebo in combination with levodopaLess wearing-off, freezing of gait and on–off fluctuation and more dyskinesia in the selegiline groupShoulson et al. (2002)
Double-blind continuation of Palhagen’s study, 140 patients10 mg selegiline vs. placebo in combination with levodopaImproved motor scores with 19% lower levodopa dose after 5 years in the selegiline groupPalhagen et al. (2006)
Retrospective and open label, 691 patients

10 mg selegiline in combination with levodopa started within 5 years of disease onset vs. levodopa alone.

4-month open label selegiline treatment initiated in the levodopa alone group

Improved motor scores after 10 years in the selegiline group.

Motor scores were improved after 4-month selegiline addition, the late started selegiline was less effective than the early started one

Mizuno et al. (2010)
Retrospective, 687 patientsEffect on disease progression of various pharmacotherapies with or without selegiline was evaluatedAt least 3 years selegiline treatment of early PD patients increased the time to progression (Hoehn–Yahr stage transition)Zhao et al. (2011)

Contrary to the increased life expectancy of selegiline-treated PD patients in the early observations of Birkmayer (1983) and Birkmayer et al. (1985), the Parkinson’s Disease Research Group of the UK reported increased mortality of patients treated with selegiline in combination with levodopa compared to levodopa alone during 5–7 years of follow-up (Lees 1995; Ben-Shlomo et al. 1998). However, meta-analyses of the available clinical trials with selegiline or any MAO-B inhibitors found no increase in mortality (Olanow et al. 1998; Ives et al. 2004; Macleod et al. 2005).

Based on the favorable effects of selegiline in PD, another irreversible MAO-B inhibitor, rasagiline, was introduced into the therapy. It was patented in 1995 (Youdim et al. 1995). Interestingly its methylated derivative, J-508, has already been tested in Knoll’s laboratory for MAO inhibition in the 1970s and was found to be slightly more potent in vivo compared to selegiline (Knoll et al. 1978). The pharmacological properties of rasagiline have been described by one of us (M. Y.). Its MAO inhibitory potential and selectivity in vitro are similar to those of selegiline, but in vivo it is about five times more potent probably due to pharmacokinetic differences (Youdim et al. 2001). A plethora of further preclinical studies showed rasagiline possessing a similar profile of beneficial effects as selegiline (Weinreb et al. 2010, 2011).

The effectiveness of rasagiline was evaluated in large clinical trials. In the first TEMPO study, its rapid symptomatic effect in early PD was demonstrated (Parkinson Study Group 2002). The results of the open-label extension of this trial indicated that patients on early started rasagiline treatment had better UPDRS score compared to delayed rasagiline administration during 6.5 years of follow-up, suggesting its neuroprotective property (Hauser et al. 2009). These results are similar to those found in selegiline studies. The ADAGIO study was designed to compare the effect of early vs. delayed start of rasagiline in controlled, randomized trial as well, to explore its disease-modifying property. The results, however, are contradictory because the extra benefit of early started therapy was observed only in case of the lower (1 mg/day) dose (Olanow et al. 2009). The effectiveness of rasagiline in levodopa-treated patients was also proved in the PRESTO and LARGO studies (Parkinson Study Group 2005; Rascol et al. 2005; Elmer 2013).

There are some further recently published data on the neuroprotective effect of the MAO-B inhibitors in PD. During 2007–2013, a large clinical study, NET-PD LS1, was performed, where the primary goal was to evaluate the effect of dietary supplement creatine on the progression of PD. Analysis of data of 1616 participants with mean observation time of 4.1 years revealed that 784 patients receiving MAO-B inhibitor (either selegiline or rasagiline) showed less clinical decline and this benefit was proportional to the cumulative duration of MAO-B inhibitor use. The effect of selegiline and rasagiline was not analyzed separately. These results indicate that MAO-B inhibitors may slow the disease progression (Hauser et al. 2017). A recent meta-analysis of the available clinical data confirms the effectiveness of MAO-B inhibitors both in monotherapy and in combination with levodopa. According to its results, selegiline seems to be the most effective MAO-B inhibitor in the combination therapy (Binde et al. 2018).

There are several recent reviews discussing the place of MAO-B inhibitors in the therapy of PD (Riederer and Laux 2011; Fabbrini et al. 2012; Dezsi and Vecsei 2014; Marsili et al. 2017; Dezsi and Vecsei 2017; Riederer and Muller 2018). More and more data suggest the disease-modifying effect of selegiline or other MAO-B inhibitor therapy, especially when they are started early and used long term (Muller and Mohr 2019). However, because of their symptoms-improving effect, the mechanisms behind the reported clinical benefits could not be unequivocally distinguished so far (Olanow 2009; Teo and Ho 2013).

Selegiline in Alzheimer’s disease

Based on its widely examined neuroprotective property, selegiline was also studied as a potential therapeutic tool for Alzheimer’s disease. Some smaller early trials indicated benefit on both cognitive and behavioral symptoms after 3–6 months of treatment. Good tolerability of the drug was also confirmed in these studies (Campi et al. 1990; Monteverde et al. 1990; Mangoni et al. 1991; Finali et al. 1992; Filip and Kolibas 1999). However, there were some trials that showed only slight, clinically not relevant improvements in cognitive and/or behavioral functions (Tariot et al. 1987; Burke et al. 1993). The conclusion of the meta-analyses is that selegiline may provide mild short-term benefit, but its magnitude is not clinically meaningful (Wilcock et al. 2002; Birks and Flicker 2003).

The mild benefit in Alzheimer’s disease and the neuroprotective activity shown in preclinical experiments initiated the development of new drug candidates including multitarget compounds. Molecules containing MAO and cholinesterase inhibitory pharmacophores were designed and found having neuroprotective activities on various in vitro and in vivo animal models (Weinreb et al. 2012; Unzeta et al. 2016). However, no clinical data with these compounds have been reported so far.

Delivery forms of selegiline

Based on the early clinical data of Birkmayer’s studies, selegiline was first licensed in Hungary in 1977 by Chinoin Pharmaceuticals under the brand name of Jumex®. At that time, it was recommended for alleviation of on–off phenomenon in levodopa-treated PD patients. Some years later, it was also approved in the same therapeutic indication in UK (1982) and in the USA as an orphan drug in 1989.

After the previously discussed clinical trials, the use of selegiline tablets was extended to early monotherapy of PD in the European Union in 1993 and in the USA in 1997. Since then the drug has been marketed worldwide.

After oral administration, selegiline undergoes extensive first pass metabolism and systemic exposure of its metabolites is considerably higher than that of the parent compound. R-Methamphetamine is its primary metabolite that is partially converted to R-amphetamine. In low quantity, desmethylselegiline and selegiline-N -oxide are also formed as shown in Fig. 1 (Heinonen et al. 1989; Szoko et al. 1999; Tabi et al. 2003; Shin 1997). These metabolites are pharmacologically active and their contribution to dopaminergic and neuroprotective effects of selegiline was suggested on the basis of extensive preclinical experiments (Szende et al. 2001; Magyar et al. 2004, 2006, 2010). However, Sandler et al. reported that substitution of selegiline treatment by its metabolites (mixture of R-methamphetamine and R-amphetamine) resulted in loss of clinical effect, suggesting no contribution of amphetamines to the clinical benefit in Parkinson’s disease (Elsworth et al. 1982; Stern et al. 1983). In clinical trials, selegiline was found to be well tolerated with similar side effect profile to that of placebo and no amphetamine-related adverse events were observed (Shoulson 1992; Palhagen et al. 1998; Shoulson et al. 2002; Palhagen et al. 2006; Mizuno et al. 2017). The weaker psychotropic effect and dependence liability of R-amphetamines compared to the S-enantiomers were shown in several preclinical studies supporting the findings of the clinical reports (Nickel et al. 1994; Yasar et al. 1993).

Scheme of metabolic transformation of selegiline. The thick arrow indicates the main metabolic step (the formation of R-methamphetamine)
Fig. 1
Scheme of metabolic transformation of selegiline. The thick arrow indicates the main metabolic step (the formation of R-methamphetamine)

To improve its bioavailability, new delivery forms of selegiline were also developed. Orally disintegrating tablets (ODT) are characterized by rapid drug release into saliva. A fraction of the active pharmaceutical ingredient absorbs through the buccal mucosa, avoiding thus the first pass metabolism and providing fast onset of action. According to comparative pharmacokinetic studies of conventional and ODT formulations, selegiline plasma exposure of 1.25 mg ODT was comparable to that of 10 mg conventional tablet. Plasma levels of metabolites were considerably lower in case of the ODT preparation (Clarke et al. 2003a). Comparative clinical trial of 1.25–2.5 mg selegiline ODT and 10 mg conventional tablets revealed similar efficacy and safety (Clarke et al. 2003b). Based on this and some further clinical data, selegiline ODT was approved by FDA in 2006 and EMA in 2010 as an adjunctive therapy to levodopa in PD. By reviewing the available clinical data, we concluded that the clinical advantage of the clear pharmacokinetic improvement is not well justified. However, the patients’ preference, because of the convenience of ODT use, especially in patients with swallowing difficulties, should be acknowledged (Tabi et al. 2013).

Another innovative formulation, selegiline transdermal system (STS), was developed to avoid first pass metabolism. Using STS, the absolute bioavailability increased to 73% from 4% observed after oral selegiline administration (Azzaro et al. 2007). However, the high and sustained plasma concentration of selegiline after STS administration results in non-selective inhibition of MAO isoforms in the brain. In early clinical trials, high, probably non-selective, dose of selegiline was found to have antidepressant activity, but the risk of cheese effect hindered its use in this indication (Mann et al. 1989; Sunderland et al. 1994). It was also reported that even chronic daily oral treatment of parkinsonian patients with MAO-B inhibitors reduced plasma MAO-A activity by about 70% (Bartl et al. 2014), brain data, however, were not available. It was only recently demonstrated that about 33% inhibition of MAO-A was achieved in human brain after 28-day treatment with STS (6 mg/day) (Fowler et al. 2015). It is in accordance with the results of clinical trials showing its antidepressant effect. Since transdermal absorption avoids the gastrointestinal tract, no considerable intestinal MAO-A inhibition was expected and was first confirmed in an animal study (Mawhinney et al. 2003). Low risk of cheese effect was thus supposed.

Short-term placebo-controlled studies of 6 and 8 weeks in adult patients with major depressive disorder demonstrated statistically significant antidepressant activity of STS compared to placebo. The safety profile of the active compound was similar to that of placebo except for application-site reactions (Bodkin and Amsterdam 2002; Amsterdam 2003; Feiger et al. 2006). There was no hypertensive effect (cheese effect) observed with even consuming tyramine-enriched diet (Blob et al. 2007). The long-term effectiveness of STS was also demonstrated for prevention of relapse in those major depressive patients who initially responded to the preparation. In the STS group, less patients experienced relapse and the time till relapse was also longer compared to placebo (Amsterdam and Bodkin 2006). One 12-week study conducted on adolescents, however, failed to show its superiority to placebo likely due to the high placebo response rate (DelBello et al. 2014). STS has FDA approval from 2006 for the treatment of major depressive disorder in adults.

Transdermal selegiline was also studied for alleviation of nicotine and cocaine dependence. As it increases dopamine level in the brain, it was supposed it might reduce craving. Previously in a smaller trial adding oral selegiline to nicotine patch doubled the 52-week continuous abstinence rate, although the difference was not significant. The need of nicotine replacement in the selegiline group was mitigated, probably due to reduced craving (Biberman et al. 2003). However, in placebo-controlled trials STS failed to improve the effectiveness of cognitive behavior intervention in smoking abstinence (Killen et al. 2010; Kahn et al. 2012). In case of cocaine dependence, although preliminary data were promising the controlled clinical trial with STS also failed to show significant effect compared to placebo (Elkashef et al. 2006).

Future perspectives

After more than half a century history of the first selective MAO-B inhibitor selegiline and its almost 40-year use in the treatment of PD, there is still a continuous interest in studying the unexplored activities of selegiline and other MAO inhibitors.

Promising cardio-metabolic effects of selegiline in animal studies were reported by several research groups. Selegiline showed antioxidant activity and reduced the fat accumulation in the liver of rats on lipid-rich diet (Bekesi et al. 2012). It also improved the metabolism and inflammation in adipose tissue of high-fat, high-sucrose diet-fed rats (Nagy et al. 2018). Its cytoprotective effect was shown in a rabbit model of chronic heart failure by reducing plasma norepinephrine, cardiac oxidative stress and myocyte apoptosis (Qin et al. 2003). MAO-B was also identified as a source of oxidative stress in the vasculature, especially in diabetes (Sturza et al. 2015). MAO-B inhibition by selegiline improved vascular function of human mammary arteries in patients with coronary heart disease regardless of the presence of diabetes (Lighezan et al. 2016). Alleviation of vascular hyperpermeability by selegiline was also demonstrated after hemorrhagic shock (Tharakan et al. 2010) and thermal injury (Whaley et al. 2009).

Potential anticancer activity of MAO inhibitors was also suggested. Overexpression of MAO in various cancer cells was reported and inhibition of the enzyme resulted in antiproliferative effect (Shih 2018; Gaur et al. 2019). Most data come from in vitro experiments, but phenelzine, a non-selective MAO inhibitor, is already in a phase II clinical trial for treatment of non-metastatic recurrent prostate cancer [ClinicalTrials.gov Identifier: NCT02217709], suggesting the clinical relevance of the anticancer activity of MAO inhibitors. High-dose selegiline itself was reported to exert cytotoxic effects on various cancer cell lines in vitro. Millimolar concentration of selegiline was shown to induce apoptotic cell death in melanoma cell line (Szende et al. 2000) and in acute myelogenous leukemia cells by inhibition of the mitochondrial respiration (Ryu et al. 2018). These very high concentrations, however, may suggest MAO-independent mechanisms that remain to be explored.

The several distinct pharmacological activities observed in in vitro and in animal experiments are really interesting, but still far from clinical relevance. The diversity of these effects may indicate either not yet characterized multiple functions of MAO enzyme protein or other targets of MAO inhibitor compounds.

Abbreviations

ADL

Activity of daily living

MAO

Monoamine oxidase

ODT

Orally disintegrating tablets

PD

Parkinson’s disease

STS

Selegiline transdermal system

UPDRS

Unified Parkinson’s disease rating scale

Notes

Publisher's Note:

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Open access funding provided by Semmelweis University (SE). The authors acknowledge the financial support of Grants 2018-1.3.1-VKE-2018-00030, GINOP 2.3.2-2015-16-00034 and Ministry of Human Capacities, Hungary Grant: 20391-3/2018/FEKUSTRAT.

References

1 

    Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993. 8: Suppl 1, pp.S36-40

2 

    Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003. 64: 2, pp.208-214

3 

    Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006. 26: 6, pp.579-586, doi: 10.1097/01.jcp.0000239794.37073.70

4 

    Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol 2007. 47: 10, pp.1256-1267, doi: 10.1177/0091270007304779

5 

    Bartl J, Muller T, Grunblatt E, Gerlach M, Riederer P. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm (Vienna) 2014. 121: 4, pp.379-383, doi: 10.1007/s00702-013-1120-z

6 

    Bekesi G, Tulassay Z, Lengyel G, Schaff Z, Szombath D, Stark J, Marczell I, Nagy-Repas P, Adler I, Dinya E, Racz K, Magyar K. The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model. J Neural Transm (Vienna) 2012. 119: 1, pp.25-30, doi: 10.1007/s00702-011-0666-x

7 

    Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ. Investigation by Parkinson’s Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry. BMJ 1998. 316: 7139, pp.1191-1196, doi: 10.1136/bmj.316.7139.1191

8 

    Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003. 98: 10, pp.1403-1407

9 

    Binde CD, Tvete IF, Gasemyr J, Natvig B, Klemp M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br J Clin Pharmacol 2018. 84: 9, pp.1917-1927, doi: 10.1111/bcp.13651

10 

    Birkmayer W. Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1983. 95: , pp.103-105

11 

    Birkmayer W, Hornykiewicz O. The l-dihydroxyphenylalanine (l-DOPA) effect in Parkinson’s syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1962. 203: , pp.560-574

12 

    Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975. 36: 3–4, pp.303-326

13 

    Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with ‘Madopar’ and l-deprenil in Parkinson’s disease. A long-term study. Lancet 1977. 1: 8009, pp.439-443

14 

    Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 1985. 64: 2, pp.113-127

15 

    Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 2003. , doi: 10.1002/14651858.cd000442

16 

    Blob LF, Sharoky M, Campbell BJ, Kemper EM, Gilmor MG, VanDenberg CM, Azzaro AJ. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 h. CNS Spectr 2007. 12: 1, pp.25-34

17 

    Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002. 159: 11, pp.1869-1875, doi: 10.1176/appi.ajp.159.11.1869

18 

    Brannan T, Yahr MD. Comparative study of selegiline plus l-dopa-carbidopa versus l-dopa-carbidopa alone in the treatment of Parkinson’s disease. Ann Neurol 1995. 37: 1, pp.95-98, doi: 10.1002/ana.410370117

19 

    Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. l-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993. 41: 11, pp.1219-1225

20 

    Campi N, Todeschini GP, Scarzella L. Selegiline versus l-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 1990. 12: 4, pp.306-314

21 

    Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna) 2003. 110: 11, pp.1241-1255, doi: 10.1007/s00702-003-0036-4

22 

    Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm (Vienna) 2003. 110: 11, pp.1257-1271, doi: 10.1007/s00702-003-0042-6

23 

    Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 1970. 225: 5235, pp.817-820

24 

    DelBello MP, Hochadel TJ, Portland KB, Azzaro AJ, Katic A, Khan A, Emslie G. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents. J Child Adolesc Psychopharmacol 2014. 24: 6, pp.311-317, doi: 10.1089/cap.2013.0138

25 

    Dezsi L, Vecsei L. Safinamide for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 2014. 23: 5, pp.729-742, doi: 10.1517/13543784.2014.897694

26 

    Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord: Drug Targets 2017. 16: 4, pp.425-439, doi: 10.2174/1871527316666170124165222

27 

    Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F, Collins J, Jones K, Boardman K, Sather M. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend 2006. 85: 3, pp.191-197, doi: 10.1016/j.drugalcdep.2006.04.010

28 

    Elmer LW. Rasagiline adjunct therapy in patients with Parkinson’s disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013. 19: 11, pp.930-936, doi: 10.1016/j.parkreldis.2013.06.001

29 

    Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. J Neural Transm 1982. 54: 1–2, pp.105-110

30 

    Fabbrini G, Abbruzzese G, Marconi S, Zappia M. Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol 2012. 35: 3, pp.134-140, doi: 10.1097/WNF.0b013e318255838b

31 

    Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006. 67: 9, pp.1354-1361

32 

    Filip V, Kolibas E. Selegiline in the treatment of Alzheimer’s disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 1999. 24: 3, pp.234-243

33 

    Finali G, Piccirilli M, Oliani C, Piccinin GL. Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Ital J Neurol Sci 1992. 13: 2, pp.141-148

34 

    Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 2011. 100: , pp.169-190, doi: 10.1016/b978-0-12-386467-3.00009-1

35 

    Finberg JP, Youdim MB. Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 1983. 22: 3 Spec No, pp.441-446

36 

    Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 2015. 40: 3, pp.650-657, doi: 10.1038/npp.2014.214

37 

    Friedhoff AJ. Deprenyl and the progression of Parkinson’s disease. Science 1990. 249: 4966, pp.303-304

38 

    Gaur S, Gross ME, Liao CP, Qian B, Shih JC. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate 2019. 79: 6, pp.667-677, doi: 10.1002/pros.23774

39 

    Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology 1996. 47: 6 Suppl 3, pp.S137-145

40 

    Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature 1977. 265: 5589, pp.80-81

41 

    Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord 2009. 24: 4, pp.564-573, doi: 10.1002/mds.22402

42 

    Hauser RA, Li R, Perez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer duration of MAO-b inhibitor exposure is associated with less clinical decline in Parkinson’s disease: an analysis of NET-PD LS1. J Parkinsons Dis 2017. 7: 1, pp.117-127, doi: 10.3233/jpd-160965

43 

    Heinonen EH, Myllyla V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijarvi M, Kotila M, Rinne UK. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand Suppl 1989. 126: , pp.93-99

44 

    Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004. 329: 7466, pp.593, doi: 10.1136/bmj.38184.606169.AE

45 

    Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968. 17: 7, pp.1285-1297

46 

    Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, Montoya I, Yu E, Elkashef A. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res 2012. 14: 3, pp.377-382, doi: 10.1093/ntr/ntr143

47 

    Killen JD, Fortmann SP, Murphy GM, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010. 105: 9, pp.1660-1668, doi: 10.1111/j.1360-0443.2010.03020.x

48 

    Knoll JMagyar K. Selective inhibitors of MAO-B with different pharmacological profiles. Monoamine oxidases and their selective inhibition 1979. Budapest Pergamon Press, pp.23-36

49 

    Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972. 5: , pp.393-408

50 

    Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965. 155: 1, pp.154-164

51 

    Knoll J, Ecsery Z, Magyar K, Satory E. Novel (−)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 1978. 27: 13, pp.1739-1747, doi: 10.1016/0006-2952(78)90550-6

52 

    Konradi C, Kornhuber J, Froelich L, Fritze J, Heinsen H, Beckmann H, Schulz E, Riederer P. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989. 33: 2, pp.383-400

53 

    Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson’s disease? Results from a 5-year study. The Norwegian–Danish Study Group. Eur J Neurol 1999. 6: 5, pp.539-547

54 

    Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease Parkinson’s Disease Research Group of the United Kingdom. BMJ 1995. 311: 7020, pp.1602-1607, doi: 10.1136/bmj.311.7020.1602

55 

    Lighezan R, Sturza A, Duicu OM, Ceausu RA, Vaduva A, Gaspar M, Feier H, Vaida M, Ivan V, Lighezan D, Muntean DM, Mornos C. Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease. Can J Physiol Pharmacol 2016. 94: 10, pp.1040-1047, doi: 10.1139/cjpp-2015-0580

56 

    Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson’s disease. Cochrane Database Syst Rev 2005. , doi: 10.1002/14651858.cd004898.pub2

57 

    Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Acad Sci Hung 1967. 32: 4, pp.377-387

58 

    Magyar K, Ecseri Z, Bernáth G, Sátory É, Knoll JMagyar K. Sturcture-activity relationship of selective inhibitors of MAO-B. Monoamine oxidases and their selective inhibition 1979. Budapest Pergamon Press, pp.11-21

59 

    Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of (−)-deprenyl. Curr Med Chem 2004. 11: 15, pp.2017-2031

60 

    Magyar K, Palfi M, Jenei V, Szoko E. Deprenyl: from chemical synthesis to neuroprotection. J Neural Transm Suppl 2006. 71: , pp.143-156

61 

    Magyar K, Szende B, Jenei V, Tabi T, Palfi M, Szoko E. R-Deprenyl: pharmacological spectrum of its activity. Neurochem Res 2010. 35: 12, pp.1922-1932, doi: 10.1007/s11064-010-0238-8

62 

    Mally J, Kovacs AB, Stone TW. Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson’s disease. J Neurol Sci 1995. 134: 1–2, pp.143-145

63 

    Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991. 31: 2, pp.100-107, doi: 10.1159/000116655

64 

    Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP. A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989. 46: 1, pp.45-50

65 

    Marsili L, Marconi R, Colosimo C. Treatment strategies in early Parkinson’s Disease. Int Rev Neurobiol 2017. 132: , pp.345-360, doi: 10.1016/bs.irn.2017.01.002

66 

    Maruyama W, Naoi M. “70th Birthday Professor Riederer” induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?. J Neural Transm (Vienna) 2013. 120: 1, pp.83-89, doi: 10.1007/s00702-012-0876-x

67 

    Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003. 55: 1, pp.27-34, doi: 10.1211/002235702478

68 

    Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N. Early addition of selegiline to l-Dopa treatment is beneficial for patients with Parkinson disease. Clin Neuropharmacol 2010. 33: 1, pp.1-4, doi: 10.1097/WNF.0b013e3181bbf45c

69 

    Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N. A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early parkinson disease. Clin Neuropharmacol 2017. 40: 5, pp.201-207, doi: 10.1097/wnf.0000000000000239

70 

    Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 1990. 12: 4, pp.315-322

71 

    Muller T, Mohr JD. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opin Drug Metab Toxicol 2019. 15: 5, pp.429-435, doi: 10.1080/17425255.2019.1607292

72 

    Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1991. 136: , pp.70-72

73 

    Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord 1993. 8: Suppl 1, pp.S41-44

74 

    Myllyla VV, Sotaniemi KA, Hakulinen P, Maki-Ikola O, Heinonen EH. Selegiline as the primary treatment of Parkinson’s disease—a long-term double-blind study. Acta Neurol Scand 1997. 95: 4, pp.211-218

75 

    Nagy CT, Koncsos G, Varga ZV, Baranyai T, Tuza S, Kassai F, Ernyey AJ, Gyertyan I, Kiraly K, Olah A, Radovits T, Merkely B, Bukosza N, Szenasi G, Hamar P, Mathe D, Szigeti K, Pelyhe C, Jelemensky M, Onodi Z, Helyes Z, Schulz R, Giricz Z, Ferdinandy P. Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats. Br J Pharmacol 2018. 175: 18, pp.3713-3726, doi: 10.1111/bph.14437

76 

    Naoi M, Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des 2010. 16: 25, pp.2799-2817

77 

    Nickel B, Szelenyi I, Schulze G. Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals. Clin Pharmacol Ther 1994. 56: 6 Pt 2, pp.757-767, doi: 10.1038/clpt.1994.206

78 

    O’Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 1983. 322: 3, pp.198-202

79 

    Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Neurology 2009. 72: 7 Suppl, pp.S59-64, doi: 10.1212/WNL.0b013e318199068b

80 

    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995. 38: 5, pp.771-777, doi: 10.1002/ana.410380512

81 

    Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Maki-Ikola O, Rinne UK. Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 1998. 51: 3, pp.825-830

82 

    Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009. 361: 13, pp.1268-1278, doi: 10.1056/NEJMoa0809335

83 

    Palhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Maki-Ikola O, Palm R, Turunen J. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998. 51: 2, pp.520-525

84 

    Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006. 66: 8, pp.1200-1206, doi: 10.1212/01.wnl.0000204007.46190.54

85 

    Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989. 321: 20, pp.1364-1371, doi: 10.1056/nejm198911163212004

86 

    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993. 328: 3, pp.176-183, doi: 10.1056/nejm199301213280305

87 

    Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol 1996. 39: 1, pp.29-36, doi: 10.1002/ana.410390106

88 

    Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002. 59: 12, pp.1937-1943

89 

    Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005. 62: 2, pp.241-248, doi: 10.1001/archneur.62.2.241

90 

    Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999. 6: 2, pp.141-150

91 

    Qin F, Shite J, Mao W, Liang CS. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol 2003. 461: 2–3, pp.149-158

92 

    Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005. 365: 9463, pp.947-954, doi: 10.1016/s0140-6736(05)71083-7

93 

    Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (−)deprenyl administration. J Neural Transm 1978. 43: 3–4, pp.271-277

94 

    Riederer P, Laux G. MAO-inhibitors in Parkinson’s disease. Exp Neurobiol 2011. 20: 1, pp.1-17, doi: 10.5607/en.2011.20.1.1

95 

    Riederer P, Muller T. Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects. J Neural Transm (Vienna) 2018. 125: 11, pp.1751-1757, doi: 10.1007/s00702-018-1876-2

96 

    Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986. 46: 5, pp.1359-1365

97 

    Riederer P, Youdim MB, Rausch WD, Birkmayer W, Jellinger K, Seemann D. On the mode of action of l-deprenyl in the human central nervous system. J Neural Transm 1978. 43: 3–4, pp.217-226

98 

    Riederer P, Jellinger K, Seemann DTipton KF, Dostert P, Strolin-Benedetti M. Monoamine oxidase and parkinsonism. Monoamine oxidase and disease 1984. London Academic Press, pp.403-415

99 

    Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MB. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of l-deprenyl. Adv Neurol 1987. 45: , pp.111-118

100 

    Ryu I, Ryu MJ, Han J, Kim SJ, Lee MJ, Ju X, Yoo BH, Lee YL, Jang Y, Song IC, Chung W, Oh E, Heo JY, Kweon GR. l-Deprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration. Oncol Rep 2018. 40: 6, pp.3869-3878, doi: 10.3892/or.2018.6753

101 

    Schulzer M. Treatment of Parkinson’s disease: disagreements. Ann Neurol 1997. 41: 6, pp.833-834, doi: 10.1002/ana.410410622

102 

    Shih JC. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm (Vienna) 2018. 125: 11, pp.1553-1566, doi: 10.1007/s00702-018-1927-8

103 

    Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997. 25: 6, pp.657-662

104 

    Shoulson I. An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. Eur Neurol 1992. 32: Suppl 1, pp.46-53, doi: 10.1159/000116869

105 

    Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002. 51: 5, pp.604-612, doi: 10.1002/ana.10191

106 

    Stern GM, Lees AJ, Hardie RJ, Sandler M. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson’s disease. Acta Neurol Scand Suppl 1983. 95: , pp.113-116

107 

    Sturza A, Duicu OM, Vaduva A, Danila MD, Noveanu L, Varro A, Muntean DM. Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes. Can J Physiol Pharmacol 2015. 93: 7, pp.555-561, doi: 10.1139/cjpp-2014-0544

108 

    Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994. 51: 8, pp.607-615

109 

    Szende B, Magyar K, Szegedi Z. Apoptotic and antiapoptotic effect of (−)deprenyl and (−)-desmethyl–deprenyl on human cell lines. Neurobiology (Bp) 2000. 8: 3–4, pp.249-255

110 

    Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K. Anti-apoptotic and apoptotic action of (−)-deprenyl and its metabolites. J Neural Transm (Vienna) 2001. 108: 1, pp.25-33, doi: 10.1007/s007020170094

111 

    Szoko E, Kalasz H, Magyar K. Biotransformation of deprenyl enantiomers. Eur J Drug Metab Pharmacokinet 1999. 24: 4, pp.315-319

112 

    Szoko E, Tabi T, Riederer P, Vecsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline. Parkinson’s disease. J Neural Transm (Vienna) 2018. 125: 11, pp.1735-1749, doi: 10.1007/s00702-018-1853-9

113 

    Tabi T, Magyar K, Szoko E. Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine. Electrophoresis 2003. 24: 15, pp.2665-2673, doi: 10.1002/elps.200305468

114 

    Tabi T, Szoko E, Vecsei L, Magyar K. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol 2013. 9: 5, pp.629-636, doi: 10.1517/17425255.2013.781152

115 

    Takahashi M, Yuasa R, Imai T, Tachibana H, Yorifuji S, Nakamura Y, Ogawa N. Selegiline (l-deprenyl) and l-dopa treatment of Parkinson’s disease: a double-blind trial. Intern Med 1994. 33: 9, pp.517-524

116 

    Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, Thompson K, Cohen RM. Cognitive effects of l-deprenyl in Alzheimer’s disease. Psychopharmacology 1987. 91: 4, pp.489-495

117 

    Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease. Transl Neurodegener 2013. 2: 1, pp.19, doi: 10.1186/2047-9158-2-19

118 

    Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989. 245: 4917, pp.519-522

119 

    Tharakan B, Whaley JG, Hunter FA, Smythe WR, Childs EW. (−)-Deprenyl inhibits vascular hyperpermeability after hemorrhagic shock. Shock 2010. 33: 1, pp.56-63, doi: 10.1097/SHK.0b013e3181a7fb7c

120 

    Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MB, Tipton KF, Marco-Contelles J. Multi-target directed donepezil-like ligands for Alzheimer’s disease. Front Neurosci 2016. 10: , pp.205, doi: 10.3389/fnins.2016.00205

121 

    Varga E, Tringer L. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropionyl-HCl, “E-250”). Acta Med Acad Sci Hung 1967. 23: 3, pp.289-295

122 

    Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010. 92: 3, pp.330-344, doi: 10.1016/j.pneurobio.2010.06.008

123 

    Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA. Neuroprotective profile of the multitarget drug rasagiline in Parkinson’s disease. Int Rev Neurobiol 2011. 100: , pp.127-149, doi: 10.1016/b978-0-12-386467-3.00007-8

124 

    Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment. Curr Drug Targets 2012. 13: 4, pp.483-494

125 

    Whaley JG, Tharakan B, Smith B, Hunter FA, Childs EW. (−)-Deprenyl inhibits thermal injury-induced apoptotic signaling and hyperpermeability in microvascular endothelial cells. J Burn Care Res 2009. 30: 6, pp.1018-1027, doi: 10.1097/BCR.0b013e3181bfb825

126 

    Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer’s disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 2002. 17: 2, pp.175-183

127 

    Yasar S, Schindler CW, Thorndike EB, Szelenyi I, Goldberg SR. Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 1993. 265: 1, pp.1-6

128 

    Youdim M, Finberg JP, Levy R, Sterling J, Lerner D (1995) R-Enantiomers of N-propargyl-amino indian compounds. Their preparation and pharmaceuticals containing them. US Patent 5,457,133

129 

    Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001. 132: 2, pp.500-506, doi: 10.1038/sj.bjp.0703826

130 

    Zhao YJ, Wee HL, Au WL, Seah SH, Luo N, Li SC, Tan LC. Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat Disord 2011. 17: 3, pp.194-197, doi: 10.1016/j.parkreldis.2010.11.010
https://www.researchpad.co/tools/openurl?pubtype=article&doi=10.1007/s00702-019-02082-0&title=Selegiline: a molecule with innovative potential&author=Tamás Tábi,László Vécsei,Moussa B. Youdim,Peter Riederer,Éva Szökő,&keyword=Selegiline,Monoamine oxidase type B inhibitors,Parkinson’s disease,Dopamine,Neuroprotection,&subject=Neurology and Preclinical Neurological Studies - Review Article,